FDA granted priority review status to lenvatinib mesylate as a treatment for progressive radioactive iodine-refractory differentiated thyroid cancer.
FRANCIS GILES was named deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
CANCER TREATMENT CENTERS OF AMERICA launched a fertility preservation program, OncoPrez, at its hospitals in Chicago, Philadelphia and Tulsa.
THE INDIANA UNIVERSITY Melvin and Bren Simon Cancer Center was recognized by NCI as a designated cancer center, and had their support grant increased by 20 percent, following an in-depth peer review.
ZHU CHEN was honored by the American Association for Cancer Research with its Award for Distinguished Public Service and Global Impact in Cancer Research in Biomedical Science.
LILI YANG received the $2.3 million Director's New Innovator Award from NIH for research into developing ways to genetically program blood stem cells to attack cancers. Yang is an assistant professor of microbiology, immunology and molecular genetics at UCLA Jonsson Comprehensive Cancer Center.
The fourth edition of the European Code Against Cancer was published by the International Agency for Research on Cancer, with the participation of the European Commission.
THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY published a revised template for survivorship care plans.
The American Society of Clinical Oncology endorsed a joint clinical practice guideline on molecular testing published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
THE ROBERT H. LURIE COMPREHENSIVE CANCER CENTER and the Northwestern Medicine Developmental Therapeutics Institute entered into an alliance with Perthera Inc. to conduct a translational research program designed to assess the utility of integration of next generation sequencing, proteomic, and phospho-proteomic data in oncology developmental therapeutics and clinical practice.
